4.7 Review

Current status and application of proton therapy for esophageal cancer

Journal

RADIOTHERAPY AND ONCOLOGY
Volume 164, Issue -, Pages 27-36

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2021.09.004

Keywords

Esophageal cancer; Proton therapy; Intensity modulated radiation therapy; Dosimetry; Lymphopenia; Total toxicity burden

Funding

  1. National Cancer Institute, National Institutes of Health [P30 CA016672]

Ask authors/readers for more resources

Esophageal cancer remains a leading cause of cancer death globally. While early-stage disease can be surgically treated, locally advanced disease is typically managed with concurrent chemoradiation, with proton therapy showing potential benefits in reducing complications and improving survival outcomes.
Esophageal cancer remains one of the leading causes of death from cancer across the world despite advances in multimodality therapy. Although early-stage disease can often be treated surgically, the current state of the art for locally advanced disease is concurrent chemoradiation, followed by surgery whenever possible. The uniform midline tumor location puts a strong importance on the need for precise delivery of radiation that would minimize dose to the heart and lungs, and the biophysical properties of proton beam makes this modality potential ideal for esophageal cancer treatment. This review covers the current state of knowledge of proton therapy for esophageal cancer, focusing on published retrospective single- and multi-institutional clinical studies, and emerging data from prospective clinical trials, that support the benefit of protons vs photon-based radiation in reducing postoperative complications, cardiac toxicity, and severe radiation induced immune suppression, which may improve survival outcomes for patients. In addition, we discuss the incorporation of immunotherapy to the curative management of esophageal cancers in the not-too-distant future. However, there is still a lack of high-level evidence to support proton therapy in the treatment of esophageal cancer, and proton therapy has its limitations in clinical application. It is expected to see the results of future large-scale randomized clinical trials and the continuous improvement of proton radiotherapy technology. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 164 (2021) 27-36

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available